Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments-Reference-Cited by-同舟云学术

Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments

Published:2018 Issue:30 Volume:8 Page:16470-16493
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Latif Muhammad¹²³⁴⁵^ORCID,Ashraf Zaman⁶⁷⁸⁹^ORCID,Basit Sulman¹²³⁴⁵^ORCID,Ghaffar Abdul⁶¹⁰¹¹⁹^ORCID,Zafar Muhammad Sohail¹²¹³³⁴⁵^ORCID,Saeed Aamer⁶¹⁴¹⁵⁹^ORCID,Meo Sultan Ayoub¹⁶¹¹⁷¹⁸⁵

Affiliation:

1. College of Medicine

2. Centre for Genetics and Inherited Diseases (CGID)

3. Taibah University

4. Al-Madinah Al-Munawwarah

5. Kingdom of Saudi Arabia

6. Department of Chemistry

7. Allama Iqbal Open University

8. Islamabad 44000

9. Pakistan

10. University of Engineering and Technology

11. Lahore

12. Department of Restorative Dentistry

13. College of Dentistry

14. Quaid-e-Azam University

15. Islamabad

16. Department of Physiology

17. King Saud University

18. Riyadh

Abstract

This review describes hit-to-drug evolution milestones, synthetic strategies and clinical significance of novel DAAPalogues discovered for ALK inhibition which are either progressing as investigational or preclinical candidates to treat the patients with ALK⁺-NSCLC.

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2018/RA/C8RA01934G

Reference188 articles.

1. Cancer statistics, 2013

2. Cancer statistics, 2014

3. Cancer statistics, 2015

4. Cancer statistics, 2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in the development of dual ALK/ROS1 inhibitors for non-small cell lung cancer therapy;European Journal of Medicinal Chemistry;2023-09

2. Selected β2-, β3- and β2,3-Amino Acid Heterocyclic Derivatives and Their Biological Perspective;Molecules;2021-01-15

3. Design, Synthesis and Biological Evaluation of 2‐(naphthoyl) iminothiazolidin‐4‐ones as Potential Anticancer Agents;ChemistrySelect;2020-04-02

4. Design, synthesis and biological evaluation N2-(2-alkyoxy-6-aliphatic aminopyridin-3-yl)-2,4-diaminepyrimidine derivatives bearing acylamino or DBTD ‘head’ as potential ALK inhibitors;Bioorganic Chemistry;2018-12

5. Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives;European Journal of Medicinal Chemistry;2018-10